Cargando…

Baricitinib: the first immunomodulatory treatment to reduce COVID-19 mortality in a placebo-controlled trial

Detalles Bibliográficos
Autores principales:	Kalil, Andre C, Stebbing, Justin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier Ltd. 2021
Materias:	Comment
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8409093/ https://www.ncbi.nlm.nih.gov/pubmed/34480862 http://dx.doi.org/10.1016/S2213-2600(21)00358-1

Ejemplares similares

Baricitinib as the treatment of choice for hospitalised individuals with COVID-19
por: Richardson, Peter J., et al.
Publicado: (2022)

Baricitinib in COVID-19: a coming-of-age from artificial intelligence to reducing mortality
por: Mehta, Puja, et al.
Publicado: (2022)

Baricitinib for COVID-19: a suitable treatment? – Authors' reply
por: Richardson, Peter J, et al.
Publicado: (2020)

Baricitinib for patients with severe COVID-19—time to change the standard of care?
por: Supady, Alexander, et al.
Publicado: (2022)

Lessons to Europe from China for cancer treatment during the COVID-19 pandemic
por: Peng, Ling, et al.
Publicado: (2020)

The AI-Assisted Identification and Clinical Efficacy of Baricitinib in the Treatment of COVID-19
por: Richardson, Peter J., et al.
Publicado: (2022)

Developments in paediatric cancer care throughout the COVID-19 pandemic: Lessons from China
por: Boiardi, Federico, et al.
Publicado: (2022)

COVID-19: combining antiviral and anti-inflammatory treatments
por: Stebbing, Justin, et al.
Publicado: (2020)

Complement C5a inhibition: a new form of COVID-19 treatment for mechanically ventilated patients?
por: Kalil, Andre C, et al.
Publicado: (2022)

In-vitro evaluation of the immunomodulatory effects of Baricitinib: Implication for COVID-19 therapy
por: Petrone, Linda, et al.
Publicado: (2021)

Baricitinib as potential treatment for 2019-nCoV acute respiratory disease
por: Richardson, Peter, et al.
Publicado: (2020)

Immunomodulatory and immunosuppressive medication modification among patients with rheumatic diseases at the time of COVID-19 vaccination
por: Barbhaiya, Medha, et al.
Publicado: (2022)

Remdesivir saves lives. Were 3 years needed to learn that?
por: Kalil, Andre C
Publicado: (2023)

Zibotentan in systemic sclerosis-associated chronic kidney disease: a phase II randomised placebo-controlled trial
por: Stern, Edward P., et al.
Publicado: (2022)

COVID-19 challenges Brazil to comply with agenda 2030 to reduce maternal mortality
por: Guimarães, Raphael Mendonça
Publicado: (2023)

Baricitinib versus dexamethasone for adults hospitalised with COVID-19 (ACTT-4): a randomised, double-blind, double placebo-controlled trial
por: Wolfe, Cameron R, et al.
Publicado: (2022)

Pharmacological trials for long COVID: first light at the end of the tunnel
por: Buonsenso, Danilo
Publicado: (2022)

First data on COVID-19 morbidity and mortality in patients with rheumatic disease from South Korea
por: Schreiber, Karen, et al.
Publicado: (2021)

Reducing child mortality in China: successes and challenges
por: Guo, Yan, et al.
Publicado: (2016)

COVID-19 vaccines: breaking record times to first-in-human trials
por: Kim, Young Chan, et al.
Publicado: (2020)

Further validation of the efficacy of mesenchymal stem cell infusions for reducing mortality in COVID-19 patients with ARDS
por: Shetty, Ashok K., et al.
Publicado: (2021)

Comment on Brandl et al. Immediate Effects of Myofascial Release on the Thoracolumbar Fascia and Osteopathic Treatment for Acute Low Back Pain on Spine Shape Parameters: A Randomized, Placebo-Controlled Trial. Life 2021, 11, 845
por: Kudus, Alexander Leonard
Publicado: (2022)

Treatment of Atopic Dermatitis with Baricitinib: First Real-life Experience
por: ROGNER, Danielle, et al.
Publicado: (2022)

Commentary to: Hyperoxemia in postsurgical sepsis/septic shock patients is associated with reduced mortality
por: Guerrero-Gutiérrez, Manuel Alberto, et al.
Publicado: (2022)

Baricitinib for COVID-19: a suitable treatment?
por: Favalli, Ennio G, et al.
Publicado: (2020)

Hydroxychloroquine in the prevention of COVID-19 mortality
por: Jorge, April
Publicado: (2021)

Long-term consequences of COVID-19: research needs
por: Yelin, Dana, et al.
Publicado: (2020)

BARICITINIB IN HOSPITALIZED PATIENTS WITH COVID-19: META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS
por: SELVARAJ, VIJAIRAM, et al.
Publicado: (2022)

Comment on Richer et al. Night Vision and Carotenoids (NVC): A Randomized Placebo Controlled Clinical Trial on Effects of Carotenoid Supplementation on Night Vision in Older Adults. Nutrients 2021, 13, 3191
por: Green-Gomez, Marina, et al.
Publicado: (2022)

“Do Not Mix Apples with Oranges” to Avoid Misinterpretation of Placebo Effects in Manual Therapy: The Risk Is Resulting in a Fruit Basket. Comment on Molina-Àlvarez et al. Manual Therapy Effect in Placebo-Controlled Trials: A Systematic Review and Meta-Analysis. Int. J. Environ. Res. Public Health 2022, 19, 14021
por: Rossettini, Giacomo, et al.
Publicado: (2023)

Childhood cancer control during the COVID-19 pandemic
por: Luna-Fineman, Sandra, et al.
Publicado: (2021)

Can Simvastatin Reduce the Need for Immunomodulatory Drugs to Treat Uveitis?: A Prospective, Randomized, Placebo-Controlled Trial
por: Al-Janabi, Ahmed, et al.
Publicado: (2023)

Baricitinib for the treatment of rheumatoid arthritis
por: Urits, Ivan, et al.
Publicado: (2020)

Baricitinib for the Treatment of Alopecia Areata
por: Freitas, Egídio, et al.
Publicado: (2023)

First clinical trial of a MERS coronavirus DNA vaccine
por: Yoon, In-Kyu, et al.
Publicado: (2019)

Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo-controlled phase 3 trial
por: Marconi, Vincent C, et al.
Publicado: (2021)

Clinical course and mortality risk of severe COVID-19
por: Weiss, Paul, et al.
Publicado: (2020)

Increased cardiovascular mortality in African Americans with COVID-19
por: McGonagle, Dennis, et al.
Publicado: (2020)

Impact of the COVID-19 pandemic on cancer incidence and mortality
por: Wells, Chad R, et al.
Publicado: (2022)

Mechanism of baricitinib supports artificial intelligence‐predicted testing in COVID‐19 patients
por: Stebbing, Justin, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_g6nohksbipva4a7ee760fdiort